First-Line Treatment for Gout: Acute Flares and Prevention

First-line treatment for gout splits into two distinct goals: stopping the pain of an acute flare and lowering uric acid over the long term to prevent future attacks. For a flare, the front-line options are NSAIDs, colchicine, and corticosteroids, all of which have roughly similar effectiveness, so the choice comes down to what suits you best given your other health conditions and medications.¹ For the longer game of preventing flares altogether, allopurinol is the strongly recommended first-line urate-lowering drug.² The relationship between these two treatment tracks, and the practical details of each, is where most of the confusion lies.

The Three First-Line Drugs for an Acute Flare

When gout flares, urate crystals in a joint trigger a fierce inflammatory cascade. The immune system’s response, driven largely by a signaling molecule called IL-1β, causes the swelling, redness, and intense pain that make a gout attack so miserable.³ All three first-line flare treatments aim to dampen that inflammatory fire, but they do it differently.

NSAIDs (drugs like naproxen or indomethacin) are the most commonly reached-for option. They block the enzymes that produce inflammatory chemicals at the site of the flare. They work fast and are available over the counter in some formulations, but they carry well-known risks for the stomach, kidneys, and heart, which limits their use in older adults and people with kidney disease or a history of ulcers.

Colchicine takes a different route. It prevents the assembly of tiny structural filaments inside immune cells, which disrupts the whole chain of events that amplifies the inflammatory response, from the initial alarm signal to the arrival of more immune cells at the joint.⁴ Colchicine works best when started within the first day or two of a flare. At the low doses now recommended, side effects like diarrhea are less common than they used to be with the old high-dose regimens. It does interact with several other medications, however, and dose adjustments are needed for people with kidney or liver problems.

Corticosteroids (such as prednisone, or an injection directly into the swollen joint) suppress inflammation broadly. They are the go-to when neither NSAIDs nor colchicine can be used safely, and they tend to be favored for people with reduced kidney function. A network meta-analysis of 30 randomized trials found that injectable corticosteroids may perform somewhat better than other commonly used first-line options, though the certainty of that evidence was rated low to very low.⁵ Short courses of oral steroids are generally well tolerated, but repeated use can raise blood sugar and comes with its own side-effect profile.

How to Choose Between Them

Because the three options perform similarly, the decision is less about which one is “better” and more about which one is safest for you. A few practical considerations often settle the question:

Kidney disease: NSAIDs are risky for kidneys; colchicine doses need to be lowered; corticosteroids are often the safest choice.
Heart failure or cardiovascular risk: NSAIDs can worsen fluid retention and blood pressure, making corticosteroids or colchicine preferable.
Stomach ulcers or GI bleeding history: NSAIDs are the worst offender here; colchicine or a steroid injection avoids that issue.
Diabetes: Corticosteroids can spike blood sugar, so colchicine or an NSAID may be better if kidney function allows.
Drug interactions: Colchicine interacts with certain antibiotics, heart medications, and antifungals. Your pharmacist will flag these, but they matter for the choice.

For someone with no major comorbidities, any of the three is reasonable, and the choice often comes down to what has worked for them before.⁶

Allopurinol as the First-Line Urate-Lowering Drug

Flare treatment puts out individual fires. Urate-lowering therapy (ULT) turns off the faucet. Allopurinol is the strongly recommended first choice for this job, including for people with moderate-to-severe chronic kidney disease, on the basis of its effectiveness when dosed correctly, its tolerability, its safety record, and its low cost.⁷ Allopurinol works by blocking the enzyme that produces uric acid, reducing the amount your body makes in the first place.⁸

The key detail many people miss is that allopurinol needs to be titrated. You typically start at a low dose and step it up gradually until your uric acid level drops below a target, usually below 6 mg/dL. Many gout patients on allopurinol never reach that target simply because the dose is never increased past the initial prescription. One study found that after a single 100 mg dose increase, about two-thirds of patients hit their target, and with further increases nearly all of them got there, with a median final dose of 300 mg daily.⁹ Side effects from the step-ups were minimal. The FDA-approved maximum is 800 mg per day, so many people are on far less than they could be.

The HLA-B*5801 Test Before Starting Allopurinol

Allopurinol’s most serious risk is a rare but dangerous skin reaction that includes conditions like Stevens-Johnson syndrome. These reactions are estimated to affect roughly 0.1 to 0.4 percent of patients.¹⁰ The risk is concentrated in people who carry a gene variant called HLA-B*5801. Screening for this variant before starting allopurinol can help prevent these reactions, and guidelines now recommend testing, especially in populations where the variant is more common (about 5 percent or more of certain Southeast Asian, Korean, and African American groups carry it).¹¹ If you test positive, your doctor will skip allopurinol entirely and go straight to an alternative like febuxostat.

Research into implementing this test in everyday clinical practice has found that both doctors and patients welcome it as a more objective way to assess risk before committing to the drug, replacing what was otherwise a trial-and-error approach.¹²

Can You Start Allopurinol During a Flare?

For years, the standard teaching was to wait until a flare fully resolves before starting urate-lowering therapy, on the logic that shifting uric acid levels mid-flare could worsen or prolong the attack. Multiple randomized trials have now challenged that idea. In one trial, patients given allopurinol on the same day as their flare treatment showed no significant difference in pain scores from day 1 through day 10 compared with placebo, and uric acid levels dropped rapidly without worsening the flare.¹³ A second trial found the time to complete flare resolution was statistically the same whether allopurinol was started early or delayed.¹⁴ A third produced similar findings, with no meaningful difference in days to resolution.¹⁵

The American College of Rheumatology now conditionally recommends starting ULT during a flare rather than waiting. Practically, this matters because the flare visit is often the moment a patient is most motivated to act, and waiting can mean the prescription never gets started at all.

Anti-Inflammatory Prophylaxis When Starting ULT

One genuine concern when beginning allopurinol is that the shifting urate levels can temporarily trigger new flares. This is frustrating and counterintuitive for patients: you take a drug meant to prevent attacks, and it causes one. To guard against this, guidelines recommend co-prescribing a low dose of colchicine, an NSAID, or a corticosteroid for the first several months of ULT.¹⁶ This “prophylaxis” cover smooths the transition period and, just as important, helps keep patients from abandoning the drug before it has a chance to work.

Febuxostat and the Cardiovascular Safety Question

When allopurinol cannot be used, febuxostat is the main alternative. It works by the same mechanism (blocking the enzyme that produces uric acid) but has a different chemical structure. For years, a cardiovascular safety shadow hung over febuxostat. A large trial in patients with gout and pre-existing cardiovascular disease found that while heart attack and stroke rates were similar between febuxostat and allopurinol, death from cardiovascular causes was higher with febuxostat.¹⁷ That trial prompted an FDA boxed warning and made many clinicians cautious.

Subsequent real-world data has complicated the picture. A long-term Taiwanese cohort study found that febuxostat users actually had a slightly lower incidence of major cardiovascular events than allopurinol users, with the difference mainly driven by lower stroke risk.¹⁸ Meanwhile, a meta-analysis in Asian populations found febuxostat users had a slightly higher risk of acute coronary syndrome and atrial fibrillation compared with allopurinol, but no significant difference in stroke.¹⁹ The honest takeaway is that the cardiovascular story is not settled. For most patients, allopurinol remains the safer first choice; febuxostat is a reasonable alternative when allopurinol is genuinely not an option, with periodic cardiovascular monitoring.

Gout and Kidney Disease

Gout and chronic kidney disease (CKD) overlap heavily, and treating gout in someone with impaired kidneys requires extra care at every step. NSAIDs are largely off the table because they can further damage the kidneys. Colchicine doses must be reduced. Corticosteroids become the safest acute flare option in many cases.

For urate lowering, the ACR guideline still strongly recommends allopurinol even for people with moderate-to-severe CKD, though starting doses are lower and the upward titration is guided by regular uric acid monitoring to reach the same target of below 6 mg/dL.²⁰ A subgroup analysis from the STOP Gout trial compared allopurinol and febuxostat head-to-head in CKD patients and found that both achieved the uric acid target at similar rates (about 80 percent), but patients on allopurinol had fewer flares during the maintenance phase.²¹

When First-Line Flare Drugs Cannot Be Used

Some patients genuinely cannot tolerate or safely take any of the standard three flare medications. In those situations, guidelines conditionally recommend IL-1β inhibitors, drugs that directly block the inflammatory signal at the heart of a gout flare.²² Canakinumab, the best-studied of these, produced the largest pain reduction of any drug examined in the network meta-analysis mentioned earlier, outperforming corticosteroids and NSAIDs at both two days and at longest follow-up.²³ Anakinra, another IL-1 blocker, has shown rapid responses in small open-label studies of patients who had failed standard therapies.²⁴

These drugs are not first line for a reason: they are expensive, they require injection, and the evidence base is still smaller. But for the patient who cannot take NSAIDs, colchicine, or steroids, they fill a real gap.

How Tophi Shrink Once Treatment Works

Tophi, the chalky nodules of crystallized urate that develop under the skin in advanced gout, are both a cosmetic nuisance and a sign of ongoing crystal burden. The good news is that effective urate-lowering therapy gradually dissolves them. The speed at which tophi shrink is directly tied to how low the uric acid level stays: the lower the sustained level, the faster they dissolve.²⁵ Imaging studies using dual-energy CT have confirmed this, showing that when uric acid is kept well below target, crystal volume drops substantially within a year or two, though dissolution still takes many months even under ideal conditions.²⁶ When uric acid hovered above roughly 7 mg/dL, dissolution time ballooned toward infinity in modeling estimates, which underscores why hitting and staying below target matters so much.

Why So Many People Stop Taking Their Medication

Allopurinol is effective, cheap, and generally well tolerated, yet adherence rates are strikingly low. In one Israeli study, only about 17 percent of gout patients were fully adherent, with nearly half classified as having poor adherence.²⁷ A large U.S. veterans cohort found that Black and Hispanic patients had significantly lower odds of adherence compared with white patients, and that being treated by a non-rheumatologist was also associated with lower adherence.²⁸

Qualitative research into why patients stop has identified a consistent pattern. People are motivated to start when they are in pain and a doctor recommends it, but they lose motivation between flares when they feel fine. The early-treatment flares that can occur when ULT is first started are particularly damaging to adherence, because patients interpret them as the drug making things worse. Some stop after receiving poor advice about how gout management works or after not being told that the drug needs months to show its full benefit.²⁹ Prophylactic anti-inflammatory cover during the start-up phase and clear communication about the timeline are the two most actionable fixes.

Treat-to-Target and Cardiovascular Payoff

Recent evidence has added another reason to take urate lowering seriously. A treat-to-target approach, where the allopurinol dose is actively adjusted to keep uric acid below a specific threshold, was associated with fewer gout flares compared with usual care.³⁰ The economic implications are real: patients with uncontrolled gout have higher emergency department visits, greater work impairment, and higher overall healthcare costs than those whose gout is well managed. When gout is controlled, costs look no different from someone without gout at all.³¹

Diet and Lifestyle as an Adjunct

Dietary changes alone rarely bring uric acid down enough to prevent flares in someone who has established gout. But they can complement medication. The consistent findings across reviews are that high-purine foods (red meat, organ meats, certain shellfish) and alcohol (especially beer) raise uric acid, while low-fat dairy, coffee, and vitamin C supplementation are associated with lower levels.³² Weight loss in people who are overweight also reduces uric acid independently of diet composition.³³

The practical advice is to treat diet as a supporting player, not the headliner. If your uric acid is high enough to cause gout, you almost certainly need medication to control it. But eating in a way that does not actively push uric acid higher makes the medication’s job easier and may allow you to use a lower dose.

Why Humans Get Gout at All

Most mammals have an enzyme called uricase that breaks down uric acid into a much more soluble compound, keeping blood levels low. Humans, along with other great apes, lost the ability to produce functional uricase through a series of genetic mutations over millions of years. Research that reconstructed ancestral versions of the enzyme found that uricase activity had been declining steadily in primate lineages long before the gene was fully knocked out.³⁴ The reasons this happened remain debated. Some researchers have proposed that higher uric acid provided an antioxidant advantage or helped maintain blood pressure in periods of low-salt diets. Whatever the evolutionary benefit, the trade-off is that humans are uniquely vulnerable to urate crystal deposition and its consequences.

1
Current Treatment Options in Rheumatology. A Review of Gout Flare Management ↩︎
2
PubMed Central. 2020 American College of Rheumatology Guideline for the Management of Gout ↩︎
3
PubMed Central. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout ↩︎
4
PubMed. Mechanism of action of colchicine in the treatment of gout ↩︎
5
PubMed Central. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis ↩︎
6
Current Treatment Options in Rheumatology. A Review of Gout Flare Management ↩︎
7
PubMed Central. 2020 American College of Rheumatology Guideline for the Management of Gout ↩︎
8
Best Practice Journal. Overcoming gout: from acute resolution to long-term prevention ↩︎
9
PubMed. Up-titration of allopurinol in patients with gout ↩︎
10
Best Practice Journal. Overcoming gout: from acute resolution to long-term prevention ↩︎
11
PubMed. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis ↩︎
12
PLoS ONE. Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors’ and patients’ perspective ↩︎
13
PubMed. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial ↩︎
14
PubMed. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial ↩︎
15
PubMed. Does starting allopurinol prolong acute treated gout? A randomized clinical trial ↩︎
16
Exploration of Musculoskeletal Diseases. Should all people starting urate-lowering therapy for gout receive anti-inflammatory prophylaxis? ↩︎
17
PubMed. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout ↩︎
18
PubMed. Cardiovascular outcomes of febuxostat and allopurinol: A long-term Taiwanese nationwide cohort study ↩︎
19
PubMed Central. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis ↩︎
20
PubMed Central. Management of Gout and Hyperuricemia in CKD ↩︎
21
PubMed. Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial ↩︎
22
PubMed Central. Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review ↩︎
23
PubMed Central. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis ↩︎
24
PubMed Central. A pilot study of IL-1 inhibition by anakinra in acute gout ↩︎
25
PubMed. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout ↩︎
26
PubMed. Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy – a study using dual-energy computed tomography ↩︎
27
Rheumatology. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel ↩︎
28
PubMed Central. Allopurinol adherence and its predictors in gout: a national cohort study in US veterans ↩︎
29
PubMed. Optimizing adherence to allopurinol for gout: patients’ perspectives ↩︎
30
JAMA Internal Medicine. Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients With Gout ↩︎
31
PubMed. The economic burden of uncontrolled gout: how controlling gout reduces cost ↩︎
32
PubMed Central. Nonpharmacological Management of Gout and Hyperuricemia: Hints for Better Lifestyle ↩︎
33
PubMed Central. Gout and Diet: A Comprehensive Review of Mechanisms and Management ↩︎
34
PubMed Central. Evolutionary history and metabolic insights of ancient mammalian uricases ↩︎